Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | May 08, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2023 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Entity Registrant Name | Athira Pharma, Inc. | |
Entity Central Index Key | 0001620463 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 37,950,600 | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity File Number | 001-39503 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 45-3368487 | |
Entity Address, Address Line One | 18706 North Creek Parkway, | |
Entity Address, Address Line Two | Suite 104 | |
Entity Address, City or Town | Bothell, | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 98011 | |
City Area Code | 425 | |
Local Phone Number | 620-8501 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Security12b Title | Common Stock, $0.0001 par value per share | |
Trading Symbol | ATHA | |
Security Exchange Name | NASDAQ |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 105,182 | $ 95,966 |
Short-term investments | 80,799 | 104,378 |
Unbilled grant receivable | 1,227 | |
Prepaid expenses and other current assets | 6,915 | 5,962 |
Total current assets | 192,896 | 207,533 |
Restricted cash | 631 | 420 |
Property and equipment, net | 4,058 | 4,053 |
Operating lease right-of-use asset | 1,212 | 1,263 |
Long-term investments | 33,903 | 44,829 |
Other long-term assets | 72 | 55 |
Total assets | 232,772 | 258,153 |
Current liabilities: | ||
Accounts payable | 892 | 2,501 |
Accrued liabilities | 8,921 | 8,604 |
Accrued legal settlement | 10,000 | 10,000 |
Current operating lease liability | 337 | 326 |
Total current liabilities | 20,150 | 21,431 |
Operating lease liability, less current portion | 1,497 | 1,585 |
Total liabilities | 21,647 | 23,016 |
Stockholders' equity: | ||
Common stock, $0.0001 par value; 900,000,000 shares authorized at March 31, 2023 and December 31, 2022, respectively; 37,950,600 and 37,877,387 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 4 | 4 |
Additional paid-in capital | 431,504 | 428,623 |
Accumulated other comprehensive loss | (1,029) | (1,956) |
Accumulated deficit | (219,354) | (191,534) |
Total stockholders' equity | 211,125 | 235,137 |
Total liabilities and stockholders' equity | $ 232,772 | $ 258,153 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 900,000,000 | 900,000,000 |
Common stock, shares issued | 37,950,600 | 37,877,387 |
Common stock, shares outstanding | 37,950,600 | 37,877,387 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 21,293 | $ 14,460 |
General and administrative | 8,477 | 8,927 |
Total operating expenses | 29,770 | 23,387 |
Loss from operations | (29,770) | (23,387) |
Grant income | 157 | 2,234 |
Other income, net | 1,793 | 173 |
Net loss | (27,820) | (20,980) |
Unrealized gain (loss) on available-for-sale securities | 927 | (1,068) |
Comprehensive loss attributable to common stockholders | $ (26,893) | $ (22,048) |
Net loss per share attributable to common stockholders, basic | $ (0.73) | $ (0.56) |
Net loss per share attributable to common stockholders, diluted | $ (0.73) | $ (0.56) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 37,923,402 | 37,593,328 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 37,923,402 | 37,593,328 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders Equity (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit |
Beginning balance at Dec. 31, 2021 | $ 321,084 | $ 4 | $ 417,363 | $ (388) | $ (95,895) |
Beginning balance, shares at Dec. 31, 2021 | 37,379,077 | ||||
Issuance of common stock upon exercise of common stock options | 210 | 210 | |||
Issuance of common stock upon exercise of common stock options, shares | 244,981 | ||||
Stock-based compensation | 2,731 | 2,731 | |||
Unrealized (loss) gain on available-for-sale securities | (1,068) | (1,068) | |||
Net loss | (20,980) | (20,980) | |||
Ending balance at Mar. 31, 2022 | 301,977 | $ 4 | 420,304 | (1,456) | (116,875) |
Ending balance, shares at Mar. 31, 2022 | 37,624,058 | ||||
Beginning balance at Dec. 31, 2022 | 235,137 | $ 4 | 428,623 | (1,956) | (191,534) |
Beginning balance, shares at Dec. 31, 2022 | 37,877,387 | ||||
Issuance of common stock upon exercise of common stock options | $ 99 | 99 | |||
Issuance of common stock upon exercise of common stock options, shares | 73,213 | 73,213 | |||
Stock-based compensation | $ 2,782 | 2,782 | |||
Unrealized (loss) gain on available-for-sale securities | 927 | 927 | |||
Net loss | (27,820) | (27,820) | |||
Ending balance at Mar. 31, 2023 | $ 211,125 | $ 4 | $ 431,504 | $ (1,029) | $ (219,354) |
Ending balance, shares at Mar. 31, 2023 | 37,950,600 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating activities | ||
Net loss | $ (27,820,000) | $ (20,980,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation | 2,782,000 | 2,731,000 |
Depreciation expense | 236,000 | 154,000 |
Non-cash lease expense | 51,000 | 45,000 |
Amortization of premiums and accretion of discounts on available-for-sale securities, net | (331,000) | 140,000 |
Changes in operating assets and liabilities: | ||
Unbilled grant receivable | 1,227,000 | 102,000 |
Prepaid expenses and other current assets | (970,000) | 1,141,000 |
Accounts payable and accrued liabilities | (1,292,000) | 164,000 |
Operating lease liability | (77,000) | (69,000) |
Net cash used in operating activities | (26,194,000) | (16,572,000) |
Investing activities | ||
Purchases of available-for-sale securities | (9,712,000) | (17,828,000) |
Maturities of available-for-sale securities | 45,475,000 | 42,419,000 |
Purchases of property and equipment | (241,000) | (745,000) |
Net cash provided by investing activities | 35,522,000 | 23,846,000 |
Financing activities | ||
Proceeds from exercise of common stock options | 99,000 | 210,000 |
Net cash provided by financing activities | 99,000 | 210,000 |
Net increase in cash, cash equivalents and restricted cash | 9,427,000 | 7,484,000 |
Cash, cash equivalents and restricted cash, beginning of period | 96,386,000 | 110,537,000 |
Cash, cash equivalents and restricted cash, end of period | $ 105,813,000 | $ 118,021,000 |
Description of Business
Description of Business | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Business | 1. Description of Business Organization Athira Pharma, Inc. (the “Company”) was incorporated as M3 Biotechnology, Inc. in the state of Washington on March 31, 2011 and reincorporated in the state of Delaware on October 27, 2015 . In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. At The Market Common Stock Offering In January 2023, the Company entered into a sales agreement with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and BTIG, LLC, or BTIG, to sell shares of our common stock having aggregate sales proceeds of up to $ 75.0 million, from time to time, through an “at the market” (“ATM”) equity offering program under which Cantor Fitzgerald and BTIG are acting as sales agents. The Company has no t sold any securities pursuant to this ATM offering . Liquidity and Capital Resources Since the Company’s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company’s inception through March 31, 2023, it has raised aggregate net cash proceeds of $ 407.4 million primarily from the issuance of its common stock (excluding option exercises), convertible preferred stock, common stock warrants, and convertible notes. As of March 31, 2023, the Company had $ 219.9 million in cash, cash equivalents and investments and had not generated positive cash flows from operations. Since the Company’s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company’s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. Based upon the Company’s current operating plan, it estimates that its $ 219.9 million of cash, cash equivalents and investments at March 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of this report. |
Significant Accounting Policies
Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | 2 . Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). The unaudited condensed consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation. Unaudited Interim Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated balance sheet as of March 31, 2023, and unaudited condensed consolidated statements of operations and comprehensive loss, cash flows, and stockholders’ equity for the three months ended March 31, 2023 and 2022, are unaudited. The balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements as of and for the year ended December 31, 2022. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2023, and the unaudited condensed consolidated results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March 31, 2023 and 2022 are also unaudited. The unaudited condensed consolidated results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year ending December 31, 2023 or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2022 included in its Annual Report on Form 10-K filed with the SEC on March 23, 2023. Fair Value Measurements The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts. Restricted Cash Restricted cash consists of collateral pledged in connection with the Company's corporate credit cards. The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows. March 31, December 31, 2023 2022 Cash and cash equivalents $ 105,182 $ 95,966 Restricted cash 631 420 Cash, cash equivalents and restricted cash $ 105,813 $ 96,386 Grant Income In December 2020, the Company accepted a grant from the National Institute on Aging (“NIA”) of the National Institutes of Health (“NIH”) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company’s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer’s disease. Under the terms of the agreement and approval received from the NIH, the Company may receive up to an aggregate of $ 15.2 million. The Company recognizes income related to the NIH grant in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred . During the three months ended March 31, 2023 and 2022, the Company recognized grant income of $ 0.2 million and $ 2.2 million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of approximately $ 1.2 million, which is included in unbilled grant receivable on the unaudited condensed consolidated balance sheets. During the three months ended March 31, 2023 and 2022, the Company received cash of $ 1.4 million and $ 2.3 million, respectively. As of March 31, 2023 , the Company has recognized aggregate grant income of $ 15.2 million in connection with the NIH grant, equal to the total grant amount approved. The Company will no t recognize any additional grant income in connection with the NIH grant. Short-term and Long-term Investments The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the unaudited condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net. The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates . Research and Development Expenses Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company’s proprietary drug discovery platform (“ATH platform”), the Company’s drug discovery efforts and the development of its product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company’s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables. Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. General and Administrative Expenses General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. Leases The Company adopted Accounting Standards Codification (“ASC”) Topic 842 - Leases effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company’s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company’s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company’s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date, discussed in more detail below. The Company’s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company’s lease agreements do not contain residual value guarantees or covenants. The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company’s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term. Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company’s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease . Stock-based Compensation The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company’s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur. The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. Net Loss Per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company . Segments The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company’s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources . Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates . Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023 and it did no t have a material impact on its financial condition, results of operations or cash flows. |
Fair Value
Fair Value | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value | 3 . Fair Value The Company has certain assets and liabilities that are measured at fair value on a recurring basis according to a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are: Level 1 —Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 —Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3 —Inputs are generally unobservable and reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are determined using model-based techniques, including probability-based simulation methodologies. The determination of a financial instrument’s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The following tables reflect the Company’s financial asset balances measured at fair value on a recurring basis (in thousands): March 31, 2023 Level Amortized Unrealized Unrealized Fair Cash equivalents: Money market fund 1 $ 28 $ — $ — $ 28 Commercial paper 2 72,459 — ( 23 ) 72,436 Agency securities 2 17,724 7 — 17,731 Total cash equivalents $ 90,211 $ 7 $ ( 23 ) $ 90,195 Short-term investments: Commercial paper 2 24,799 — ( 55 ) 24,744 U.S. government debt and agency 2 53,278 — ( 496 ) 52,782 Corporate bonds 2 3,302 — ( 29 ) 3,273 Total short-term investments $ 81,379 $ — $ ( 580 ) $ 80,799 Long-term investments: U.S. government debt and agency 2 34,336 22 ( 455 ) 33,903 Total long-term investments $ 34,336 $ 22 $ ( 455 ) $ 33,903 December 31, 2022 Level Amortized Unrealized Unrealized Fair Cash equivalents: Money market fund 1 $ 7 $ — $ — $ 7 Commercial paper 2 78,028 — ( 26 ) 78,002 Total cash equivalents $ 78,035 $ — $ ( 26 ) $ 78,009 Short-term investments: Commercial paper 2 36,933 — ( 168 ) 36,765 U.S. government debt and agency 2 65,157 — ( 784 ) 64,373 Corporate bonds 2 3,302 — ( 62 ) 3,240 Total short-term investments $ 105,392 $ — $ ( 1,014 ) $ 104,378 Long-term investments: U.S. government debt and agency 2 45,745 — ( 916 ) 44,829 Total long-term investments $ 45,745 $ — $ ( 916 ) $ 44,829 All the commercial paper, U.S. government debt, municipal bonds and agency securities, U.S. treasury bills, and corporate bonds designated as short-term investments have an effective maturity date that is equal to or less than one year from the respective balance sheet date. Those that are designated as long-term investments have an effective maturity date that is more than one year, but less than two years, from the respective balance sheet date. As of March 31, 2023, the Company does not intend to sell any securities in unrealized loss positions, and it is not more-likely-than-not that the Company will be required to sell such securities prior to the recovery of the amortized cost basis. Based on the Company's assessment, the Company concluded all impairments as of March 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit loss allowance was not recognized and the unrealized losses for available-for-sale securities were recorded in other comprehensive loss. |
Property and Equipment, Net
Property and Equipment, Net | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, Net | 4 . Property and Equipment, Net Property and equipment consisted of the following (in thousands): March 31, December 31, 2023 2022 Lab equipment $ 653 $ 433 Office furniture, fixtures, and 712 692 Leasehold improvement 4,296 4,296 Property and equipment, at cost 5,661 5,421 Less: accumulated depreciation ( 1,603 ) ( 1,368 ) Property and equipment, net $ 4,058 $ 4,053 Depreciation expense was $ 236,000 and $ 154,000 for the three months ended March 31, 2023 and 2022 , respectively. |
Accrued Liabilities
Accrued Liabilities | 3 Months Ended |
Mar. 31, 2023 | |
Payables and Accruals [Abstract] | |
Accrued Liabilities | 5 . Accrued Liabilities Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2023 2022 Research and development expenses $ 5,599 $ 3,843 Employee compensation and benefits 1,983 3,415 Professional services and other 1,339 1,346 Total accrued liabilities $ 8,921 $ 8,604 |
Significant Agreements
Significant Agreements | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Significant Agreements | . Significant Agreements Washington State University (“WSU”) License Agreement The Company is party to an amended and restated exclusive license agreement with sublicensing terms with Washington State University (“WSU”) that the Company entered into in 2015. Under this agreement, the Company has an exclusive license to make, use, sell, and offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration. To keep in good standing, the agreement requires the Company to meet certain development milestones and pay annual maintenance fees. All contractual requirements have been met as of March 31, 2023. During the year ended December 31, 2020, the Phase 2 clinical trial milestone had been reached and a payment of $ 50,000 to WSU was recorded. The Company may also be obligated to pay the following if the related milestones are reached: • $ 300,000 – At initiation of the first Phase 3 clinical trial in the United States, European Union or Japan for the first licensed product; and • $ 600,000 – Upon receipt of marketing approval in the United States, European Union or Japan for the first licensed product. Under the terms of the agreement, the Company will pay a royalty in the mid-single digits of net sales, with the first $ 100,000 of net sales being exempt from royalty payment, and annual minimum royalty payments of $ 25,000 beginning after the first commercial sale of a licensed product. As of March 31, 2023, no sales of any licensed products had occurred and the Company had no t incurred a royalty obligation under this agreement . Additionally, the agreement allows the Company to sublicense the rights conveyed by the agreement, subject to additional payments to WSU based upon the sublicense consideration received in such event. Such amounts are dependent on the terms of the underlying sublicense and range from the mid-single digits to mid-teens of any non-sales based payments received, and low twenties of net sales based sublicense royalties. As of March 31, 2023, the Company has not entered into or incurred any liability from a sublicense agreement . |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | . Commitments and Contingencies Legal Proceedings From time to time, the Company is subject to various legal proceedings or claims that arise in the ordinary course of business. The Company accrues a liability when the Company's management believes that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. The following is a brief description of the more significant legal proceedings. Securities Class Actions On June 25, 2021 , plaintiffs Fan Wang and Hang Gao filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company and the Company’s former chief executive officer Dr. Leen Kawas, captioned Wang v. Athira Pharma, Inc., et al. , No. 2:21-cv-00861. Plaintiffs Wang and Gao assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding the Company’s business. Specifically, the Wang plaintiffs allege that the Company failed to disclose to investors that certain research conducted by Dr. Kawas was allegedly tainted by scientific misconduct during her doctoral work at WSU, including the manipulation of data, and that as a result, the defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading. The Wang plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys’ fees. That same day, on June 25, 2021 , plaintiff Harshdeep Jawandha filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company’s chief financial officer, certain members of the Company’s board of directors at the time of the Company’s initial public offering (IPO), as well as the IPO underwriters, captioned Jawandha v. Athira Pharma, Inc., et al. , No. 2:21-cv-00862. The Jawandha complaint asserts violations of Sections 11 and 15 of the Securities Act of 1933 ("Securities Act"), alleging that that the Company’s IPO registration statement was materially false and misleading because it omitted to state that certain of Dr. Kawas’s published doctoral research papers at WSU contained allegedly improperly altered images, that the research was allegedly foundational to the Company’s efforts to develop treatments for Alzheimer’s disease, and that the defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading. The Jawandha plaintiff seeks unspecified compensatory damages, and reasonable costs and expenses, including attorneys’ fees. Also on June 25, 2021 , plaintiffs Timothy Slyne and Tai Slyne filed a putative securities class action lawsuit in the U.S. District Court for the Western District of Washington against the Company, Dr. Kawas, the Company’s chief financial officer, and the same members of the Company’s board of directors and underwriters as in the Jawandha complaint, captioned Slyne v. Athira Pharma, Inc. et al. , No. 2:21-cv-00864. The Slyne complaint asserts violations of Sections 11 and 15 of the Securities Act, alleging that purported issues with Dr. Kawas’s doctoral research at WSU should have been disclosed in the Company’s IPO registration statement. The Slyne plaintiffs seek unspecified compensatory damages, reasonable costs and expenses, including attorneys’ fees, and injunctive and other equitable relief. On August 9, 2021, the court issued an order consolidating the three cases. On October 5, 2021, the district court issued an order appointing lead plaintiffs and approved their selection of lead and liaison counsel. On January 7, 2022, lead plaintiffs filed a consolidated amended complaint, which asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and Sections 11, 12, and 15 of the Securities Act. The consolidated amended complaint is brought against the Company, Dr. Kawas, the Company’s chief financial officer, certain members of the Company's board of directors at the time of the Company's IPO and secondary public offering, or SPO, and the IPO and SPO underwriters. As with the previous complaints, it is based on allegations that the IPO and SPO registration statements and/or other public statements were materially false and misleading because they omitted to state that certain of Dr. Kawas’s published doctoral research papers at WSU contained allegedly improperly altered images. Lead plaintiffs seek unspecified compensatory damages, as well as equitable and injunctive relief on behalf of themselves and the purported class. On March 8, 2022, the defendants filed a motion to dismiss lead plaintiffs’ consolidated amended complaint for failure to state a claim under the federal securities laws. On July 29, 2022, the court issued an order granting in part and denying in part the motion to dismiss. The order dismissed the Section 10(b) and Section 20(a) claims arising under the Exchange Act, dismissed the Section 11 claim arising under the Securities Act as to all defendants other than the Company and Dr. Kawas, dismissed the Section 12(a)(2) claim arising under the Securities Act as to the lead plaintiffs, and dismissed the Section 15 claim arising under the Securities Act against all defendants other than Dr. Kawas. The order permitted lead plaintiffs until August 19, 2022 to file a second consolidated amended complaint. Lead plaintiffs did not file a second consolidated amended complaint. On August 12, 2022 , defendant Dr. Kawas filed a motion for partial reconsideration of the court’s July 29, 2022 order. On October 24, 2022, the parties filed a (1) joint status report and discovery plan and (2) stipulation and case scheduling order, wherein the parties proposed deadlines for material case events, including the completion of fact discovery, expert discovery, and dispositive motion practice. On November 2, 2022, the court entered an order setting certain case deadlines. On November 4, 2022, the Company and Dr. Kawas filed their individual answers to the consolidated amended complaint. In mid-November 2022, the parties began conducting fact discovery. On March 10, 2023, following a mediation and the parties’ agreement in principle to settle the securities class action, the court entered a stipulated order setting a deadline of April 28, 2023 for the parties to file a stipulation of settlement and for lead plaintiffs to file a motion for preliminary approval of the settlement, which the parties filed on that date. The settlement is subject to preliminary and final approval by the U.S. District Court for the Western District of Washington. As a result of the foregoing, the Company recorded a legal settlement expense of $ 10.0 million in operating expenses in the fourth quarter of 2022 and an accrued liability of $ 10.0 million on the accompanying unaudited condensed consolidated balance sheets. Shareholder Derivative Actions On April 14, 2022, a shareholder derivative action was filed by plaintiff Stephen Bushansky in the U.S. District Court for the Western District of Washington against certain current and former members of the Company’s board of directors, captioned Bushansky v. Kawas et al. , No. 2:22-cv-497. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that the Company’s board of directors breached its fiduciary duties by failing to prevent alleged misstatements in the Company’s public filings, failing to discover altered images in certain research papers, and failing to take appropriate action. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and waste of corporate assets. The derivative complaint seeks unspecified damages, disgorgement of profits, benefits, and other compensation received by the individual defendants, restitution, declaratory relief, and an award of costs and expenses to the derivative plaintiff, including attorneys’ fees. On May 6, 2022, a second shareholder derivative action was filed by plaintiff Thomas Houlihan in the U.S. District Court for the Western District of Washington against certain current and former directors and officers of the Company, captioned Houlihan v. Kawas et al ., No. 2:22-cv-620. Plaintiff purports to bring the action derivatively on behalf of the Company, which is a nominal defendant to the action. The derivative complaint alleges that certain of the Company’s current and former directors and officers breached their fiduciary duties by failing to prevent alleged misstatements in the Company’s public filings and failing to take appropriate action regarding altered images in certain research papers. The derivative complaint asserts claims for violations of Section 14(a) of the Exchange Act as well as claims for breach of fiduciary duties, contribution, and indemnification. The derivative complaint seeks unspecified damages, unspecified corporate governance reforms, restitution, and an award of costs and expenses to the derivative plaintiff, including attorneys’ fees. On May 26, 2022, the court issued an order consolidating the cases and staying them until further order of the court. Government Investigations In November 2022, the Company received a Civil Investigative Demand from the Civil Division of the Department of Justice, or the Demand. The Demand seeks documents and information relating to our relationship with WSU, certain of our grant applications in 2016 and 2019 with the National Institutes of Health, or NIH, and our receipt of a NIH grant in 2020. The Company is cooperating with the Department of Justice with respect to the Demand . In February 2023, the Securities and Exchange Commission, or SEC, sent the Company a subpoena seeking documents and information relating to, among other things, our former chief executive officer's alterations of images in certain research papers. The Company is cooperating with the SEC with respect to the subpoena . The Company cannot predict the outcome of these lawsuits or government investigations. Failure by the Company to obtain a favorable resolution of these actions could have a material adverse effect on our business, results of operations and financial condition. The Company’s chances of success on the merits are still uncertain and, other than an accrual of $ 10.0 million recorded for the proposed settlement of the securities class action litigation during the year ended December 31, 2022, any possible loss or range of loss cannot be reasonably estimated and as such the Company has not otherwise recorded a liability as of March 31, 2023. Operating Leases The Company has operating leases for laboratory and office facilities in Bothell, Washington that expire in August 2027 . The initial terms of the leases range from 6.3 to 7 years and the Company has options to extend the leases for an additional five years that it is not reasonably certain to exercise . As of March 31, 2023, the Company was not party to any finance leases. The following table reconciles the Company’s undiscounted operating lease cash flows to its operating lease liability (in thousands): March 31, Remaining 2023 351 2024 480 2025 494 2026 509 Thereafter 346 Total undiscounted lease payments 2,180 Present value adjustment for minimum lease ( 346 ) Net lease liability $ 1,834 The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows: March 31, Weighted average remaining lease term (years) 4.4 Weighted average discount rate 8.1 % Operating lease expense and variable lease expense consisted of the following (in thousands): Three Months Ended March 31, 2023 2022 Operating lease expense $ 88,000 $ 89,000 Variable lease expense $ 60,000 $ 44,000 |
Common Stock
Common Stock | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Common Stock | . Common Stock Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and if declared by the Company’s board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception. The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows: March 31, December 31, 2023 2022 Shares issuable upon the exercise of outstanding 6,941,479 4,269,861 Shares available for future grant under the 2020 3,402,892 4,253,854 Shares available for future grant under the 1,295,414 916,640 Total 11,639,785 9,440,355 The Company’s 2020 Equity Incentive Plan (“2020 Plan”) provides for annual increases in the number of shares that may be issued under the 2020 Plan on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (a) 3,230,000 shares, (b) 5 % of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (c) an amount determined by the Company’s board of directors. The Company’s 2020 Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares that may be issued under the ESPP on January 1, 2021 and each subsequent January 1, thereafter, by a number of shares equal to the least of (a) 646,000 shares, (b) 1 % of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (c) an amount determined by the Company’s board of directors. Effective January 1, 2023, the Company’s 2020 Plan and ESPP reserves increased by 1,893,869 shares and 378,774 shares, respectively . |
Stock-based Compensation
Stock-based Compensation | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-based Compensation | . Stock-based Compensation Stock‑based compensation expense recognized was as follows (in thousands): Three Months Ended March 31, 2023 2022 Research and development $ 997 $ 785 General and administrative 1,785 1,946 Total stock-based compensation expense $ 2,782 $ 2,731 Valuation Assumptions The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally required significant judgment. • Fair Value of Common Stock —The fair value of each share of common stock is based on the closing price of the Company’s common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. • Risk-Free Interest Rate —The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. • Expected Volatility —Because the Company was previously privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. • Expected Term —The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term) as the Company has limited history of relevant stock option exercise activity. • Expected Dividend Yield —The Company has never paid dividends on its common stock and has no plans to pay dividends going forward. Therefore, it used an expected dividend yield of zero . The fair value of each stock option was estimated using the Black‑Scholes option‑pricing model with the following weighted-average assumptions: Three Months Ended March 31, 2023 2022 Risk-free interest rate 3.48 % 1.73 % Expected volatility 99.25 % 92.65 % Expected term (in years) 5.80 6.01 Expected dividend yield — — The grant date fair value of restricted stock units is based upon the fair market value of the Company’s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. The fair value of options granted during the three months ended March 31, 2023 and 2022 was $ 7.6 million and $ 11.9 million, respectively. The fair value of restricted stock units granted during the three months ended March 31, 2023 and 2022 was $ 0.4 million and $ 0.1 million, respectively. Stock Option and Restricted Stock Unit Activity Changes in shares available for grant under the 2020 Plan during the three months ended March 31, 2023 were as follows: Shares Shares available for grant at December 31, 2022 4,253,854 2020 Plan reserve increase on January 1, 2023 1,893,869 Options and restricted stock units granted ( 2,833,995 ) Options and restricted stock units forfeited, 89,164 Shares available for grant at March 31, 2023 3,402,892 A summary of stock option activity under the 2020 Plan for the three months ended March 31, 2023 was as follows: Shares Weighted- Weighted- Aggregate Balance at December 31, 2022 4,033,522 $ 11.75 8.40 $ 827 Granted 2,714,995 3.52 Exercised ( 73,213 ) 1.35 Forfeited/expired ( 79,831 ) 5.34 Balance at March 31, 2023 6,595,473 $ 8.56 8.84 $ 476 Expected to vest 5,040,111 $ 7.51 9.22 $ 67 Options exercisable 1,555,362 $ 11.96 7.61 $ 409 The total fair value of options granted that vested during the three months ended March 31, 2023 and 2022 was $ 2.5 million and $ 1.9 million, respectively. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company’s common stock underlying all options that were in-the-money at March 31, 2023 . The aggregate intrinsic value of options exercised was $ 0.2 million and $ 2.7 million during the three months ended March 31, 2023 and 2022, respectively, determined as of the date of option exercise. As of March 31, 2023 , there was $ 23.7 million of total unrecognized compensation cost related to unvested stock options. The Company expects to recognize this cost over a remaining weighted-average period of 2.6 years. The Company utilizes newly issued shares to satisfy option exercises. Stock options outstanding and exercisable under the 2020 Plan consisted of the following at March 31, 2023: Exercise Price ($) Shares Shares 0.16 to 4.33 3,206,263 390,211 8.93 to 19.94 3,015,489 971,954 20.55 to 29.41 373,721 193,197 Total 6,595,473 1,555,362 A summary of restricted stock unit, or RSU, activity for the three months ended March 31, 2023 is as follows: Share Weighted- Non-vested at December 31, 2022 236,339 $ 15.16 Granted 119,000 3.37 Cancelled ( 9,333 ) 6.36 Vested — — Non-vested at March 31, 2023 346,006 $ 11.34 The RSUs will vest upon achievement of certain clinical development milestones, subject to continued service to the Company during the vesting period. As of March 31, 2023 , there was $ 1.3 million of total unrecognized compensation cost related to unvested RSUs. The Company expects to recognize this cost over a remaining weighted-average period of 0.9 years. |
Net Loss Per Share Attributable
Net Loss Per Share Attributable to Common Stockholders | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share Attributable to Common Stockholders | 10. Net Loss Per Share Attributable to Common Stockholders The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Non-vested Restricted Stock Units 346,006 359,750 Stock options to purchase common stock 6,595,473 3,425,444 Employee stock purchase plan 15,079 2,955 Total 6,956,558 3,788,149 |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). The unaudited condensed consolidated financial statements include the operations of Athira Pharma, Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation. |
Unaudited Interim Condensed Financial Statements | Unaudited Interim Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated balance sheet as of March 31, 2023, and unaudited condensed consolidated statements of operations and comprehensive loss, cash flows, and stockholders’ equity for the three months ended March 31, 2023 and 2022, are unaudited. The balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements as of and for the year ended December 31, 2022. The unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2023, and the unaudited condensed consolidated results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The financial data and other information disclosed in these notes related to the three months ended March 31, 2023 and 2022 are also unaudited. The unaudited condensed consolidated results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the full year ending December 31, 2023 or any other period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2022 included in its Annual Report on Form 10-K filed with the SEC on March 23, 2023. |
Fair Value Measurements | Fair Value Measurements The carrying amounts of certain financial instruments, including cash, cash equivalents, restricted cash, investments, accounts payable and accrued expenses approximate their fair values due to the short-term nature of those amounts. |
Restricted Cash | Restricted Cash Restricted cash consists of collateral pledged in connection with the Company's corporate credit cards. The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows. March 31, December 31, 2023 2022 Cash and cash equivalents $ 105,182 $ 95,966 Restricted cash 631 420 Cash, cash equivalents and restricted cash $ 105,813 $ 96,386 |
Grant Income | Grant Income In December 2020, the Company accepted a grant from the National Institute on Aging (“NIA”) of the National Institutes of Health (“NIH”) to support its ACT-AD Phase 2 clinical trial for fosgonimeton (then-named ATH-1017), the Company’s lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer’s disease. Under the terms of the agreement and approval received from the NIH, the Company may receive up to an aggregate of $ 15.2 million. The Company recognizes income related to the NIH grant in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss as qualifying expenses under the grant agreement are incurred . During the three months ended March 31, 2023 and 2022, the Company recognized grant income of $ 0.2 million and $ 2.2 million, respectively, in connection with the NIH grant. As of December 31, 2022, the Company incurred qualifying expenses in excess of cash received of approximately $ 1.2 million, which is included in unbilled grant receivable on the unaudited condensed consolidated balance sheets. During the three months ended March 31, 2023 and 2022, the Company received cash of $ 1.4 million and $ 2.3 million, respectively. As of March 31, 2023 , the Company has recognized aggregate grant income of $ 15.2 million in connection with the NIH grant, equal to the total grant amount approved. The Company will no t recognize any additional grant income in connection with the NIH grant. |
Short-term and Long-term Investments | Short-term and Long-term Investments The Company generally invests its excess cash in investment grade short- to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term investments, and long-term investments on the unaudited condensed consolidated balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Amortization and accretion are included in other income, net. Realized gains and losses on the sale of these securities are recognized in other income, net. The Company periodically evaluates whether declines in fair values of its investments below their book value are due to expected credit losses, as well as the Company's ability and intent to hold the investment until a forecasted recovery occurs. Expected credit losses are recorded as an allowance through other income, net. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates . |
Research and Development Expenses | Research and Development Expenses Research and development expenses consist primarily of direct and indirect costs incurred for research activities, including development of the pipeline from the Company’s proprietary drug discovery platform (“ATH platform”), the Company’s drug discovery efforts and the development of its product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain the Company’s research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, and facilities and other expenses consisting of direct and allocated expenses for rent and depreciation and lab consumables. Research and development costs are expensed as incurred. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company adjusts the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. |
General and Administrative Expenses | General and Administrative Expenses General and administrative expenses consist primarily of personnel-related costs, consisting of employee salaries, related benefits, and stock-based compensation expense for employees in the executive, legal, finance and accounting, human resources, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. General and administrative costs are expensed as incurred. |
Leases | Leases The Company adopted Accounting Standards Codification (“ASC”) Topic 842 - Leases effective January 1, 2020. The Company determines if an arrangement contains a lease at inception. The Company performed an evaluation of contracts in accordance with ASC 842 and has determined it has an operating lease agreement for the laboratory and office facilities that the Company occupies. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for the Company’s use. Operating lease liabilities are based on the present value of the future minimum lease payments over the lease term. ROU assets are measured at the amount of the lease liability, adjusted for any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As the Company’s leases generally do not provide an implicit interest rate, the present value of the future minimum lease payments is determined using the Company’s incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate the Company would incur on its future lease payments over a similar term and is based on the information available to the Company at the lease commencement date, discussed in more detail below. The Company’s leases contain options to extend the leases; lease terms are adjusted for these options only when it is reasonably certain the Company will exercise these options. The Company’s lease agreements do not contain residual value guarantees or covenants. The Company has made a policy election regarding its real estate leases not to separate non-lease components from lease components, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. The Company’s lease includes variable non-lease components, such as common-area maintenance costs. The Company has elected not to record on the balance sheet a lease that has a lease term of 12 months or less and does not contain a purchase option that the Company is reasonably certain to exercise. The Company accounts for leases with initial terms of 12 months or less as operating expenses on a straight-line basis over the lease term. Lease expense is recognized within operating expenses on a straight-line basis over the terms of the lease. Incentives granted under the Company’s facilities lease, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the term of the lease . |
Stock-based Compensation | Stock-based Compensation The Company measures compensation expense for all stock-based payments to employees, officers and directors based on the estimated fair value of the award at the grant date. For stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The grant date fair value of restricted stock units is based upon the fair market value of the Company’s common stock based on its closing price as reported on the date of grant on the Nasdaq Global Select Market. Compensation expense is recognized over the requisite service period on a straight-line basis. Forfeitures are recognized as they occur. The Company records compensation expense for stock option and restricted stock unit grants subject to performance-based milestone vesting over the remaining implicit service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. |
Net Loss Per Share Attributable to Common Stockholders | Net Loss Per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company . |
Segments | Segments The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing therapeutics. The Company’s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources . |
Emerging Growth Company Status | Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act, unless early adoption is permitted. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates . |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments: Credit Losses (Topic 326) as clarified in ASU 2019-04, ASU 2019-05, and ASU 2020-02. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than-temporary impairments on investment securities are recorded. The Company adopted ASU 2016-13 effective January 1, 2023 and it did no t have a material impact on its financial condition, results of operations or cash flows. |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Cash, Cash Equivalents and Restricted Cash | The table below reconciles the balances of cash and cash equivalents and restricted cash reported on the unaudited condensed consolidated balance sheets to the balances of cash, cash equivalents and restricted cash reported on the unaudited condensed consolidated statements of cash flows. March 31, December 31, 2023 2022 Cash and cash equivalents $ 105,182 $ 95,966 Restricted cash 631 420 Cash, cash equivalents and restricted cash $ 105,813 $ 96,386 |
Fair Value (Tables)
Fair Value (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments | The following tables reflect the Company’s financial asset balances measured at fair value on a recurring basis (in thousands): March 31, 2023 Level Amortized Unrealized Unrealized Fair Cash equivalents: Money market fund 1 $ 28 $ — $ — $ 28 Commercial paper 2 72,459 — ( 23 ) 72,436 Agency securities 2 17,724 7 — 17,731 Total cash equivalents $ 90,211 $ 7 $ ( 23 ) $ 90,195 Short-term investments: Commercial paper 2 24,799 — ( 55 ) 24,744 U.S. government debt and agency 2 53,278 — ( 496 ) 52,782 Corporate bonds 2 3,302 — ( 29 ) 3,273 Total short-term investments $ 81,379 $ — $ ( 580 ) $ 80,799 Long-term investments: U.S. government debt and agency 2 34,336 22 ( 455 ) 33,903 Total long-term investments $ 34,336 $ 22 $ ( 455 ) $ 33,903 December 31, 2022 Level Amortized Unrealized Unrealized Fair Cash equivalents: Money market fund 1 $ 7 $ — $ — $ 7 Commercial paper 2 78,028 — ( 26 ) 78,002 Total cash equivalents $ 78,035 $ — $ ( 26 ) $ 78,009 Short-term investments: Commercial paper 2 36,933 — ( 168 ) 36,765 U.S. government debt and agency 2 65,157 — ( 784 ) 64,373 Corporate bonds 2 3,302 — ( 62 ) 3,240 Total short-term investments $ 105,392 $ — $ ( 1,014 ) $ 104,378 Long-term investments: U.S. government debt and agency 2 45,745 — ( 916 ) 44,829 Total long-term investments $ 45,745 $ — $ ( 916 ) $ 44,829 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | Property and equipment consisted of the following (in thousands): March 31, December 31, 2023 2022 Lab equipment $ 653 $ 433 Office furniture, fixtures, and 712 692 Leasehold improvement 4,296 4,296 Property and equipment, at cost 5,661 5,421 Less: accumulated depreciation ( 1,603 ) ( 1,368 ) Property and equipment, net $ 4,058 $ 4,053 |
Accrued Liabilities (Tables)
Accrued Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Liabilities | Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2023 2022 Research and development expenses $ 5,599 $ 3,843 Employee compensation and benefits 1,983 3,415 Professional services and other 1,339 1,346 Total accrued liabilities $ 8,921 $ 8,604 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments | The following table reconciles the Company’s undiscounted operating lease cash flows to its operating lease liability (in thousands): March 31, Remaining 2023 351 2024 480 2025 494 2026 509 Thereafter 346 Total undiscounted lease payments 2,180 Present value adjustment for minimum lease ( 346 ) Net lease liability $ 1,834 |
Weighted Average Remaining Lease Term and Weighted Average Discount Rate and Operating Lease Expense and Variable Lease Expense | The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows: March 31, Weighted average remaining lease term (years) 4.4 Weighted average discount rate 8.1 % Operating lease expense and variable lease expense consisted of the following (in thousands): Three Months Ended March 31, 2023 2022 Operating lease expense $ 88,000 $ 89,000 Variable lease expense $ 60,000 $ 44,000 |
Common Stock (Tables)
Common Stock (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Schedule of Reserved Shares of Common Stock for Future Issuance | The Company has reserved the following shares of common stock for future issuance, on an as-converted basis, as follows: March 31, December 31, 2023 2022 Shares issuable upon the exercise of outstanding 6,941,479 4,269,861 Shares available for future grant under the 2020 3,402,892 4,253,854 Shares available for future grant under the 1,295,414 916,640 Total 11,639,785 9,440,355 |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Stock-based Compensation Expense Recognized | Stock‑based compensation expense recognized was as follows (in thousands): Three Months Ended March 31, 2023 2022 Research and development $ 997 $ 785 General and administrative 1,785 1,946 Total stock-based compensation expense $ 2,782 $ 2,731 |
Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model | The fair value of each stock option was estimated using the Black‑Scholes option‑pricing model with the following weighted-average assumptions: Three Months Ended March 31, 2023 2022 Risk-free interest rate 3.48 % 1.73 % Expected volatility 99.25 % 92.65 % Expected term (in years) 5.80 6.01 Expected dividend yield — — |
Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan | Changes in shares available for grant under the 2020 Plan during the three months ended March 31, 2023 were as follows: Shares Shares available for grant at December 31, 2022 4,253,854 2020 Plan reserve increase on January 1, 2023 1,893,869 Options and restricted stock units granted ( 2,833,995 ) Options and restricted stock units forfeited, 89,164 Shares available for grant at March 31, 2023 3,402,892 |
Summary of Option Activity under the 2020 Plan | A summary of stock option activity under the 2020 Plan for the three months ended March 31, 2023 was as follows: Shares Weighted- Weighted- Aggregate Balance at December 31, 2022 4,033,522 $ 11.75 8.40 $ 827 Granted 2,714,995 3.52 Exercised ( 73,213 ) 1.35 Forfeited/expired ( 79,831 ) 5.34 Balance at March 31, 2023 6,595,473 $ 8.56 8.84 $ 476 Expected to vest 5,040,111 $ 7.51 9.22 $ 67 Options exercisable 1,555,362 $ 11.96 7.61 $ 409 |
Summary of Stock Options Outstanding and Exercisable under the 2020 Plan | Stock options outstanding and exercisable under the 2020 Plan consisted of the following at March 31, 2023: Exercise Price ($) Shares Shares 0.16 to 4.33 3,206,263 390,211 8.93 to 19.94 3,015,489 971,954 20.55 to 29.41 373,721 193,197 Total 6,595,473 1,555,362 |
Restricted Stock Units (RSUs) | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Summary of Restricted Stock Activity | A summary of restricted stock unit, or RSU, activity for the three months ended March 31, 2023 is as follows: Share Weighted- Non-vested at December 31, 2022 236,339 $ 15.16 Granted 119,000 3.37 Cancelled ( 9,333 ) 6.36 Vested — — Non-vested at March 31, 2023 346,006 $ 11.34 |
Net Loss Per Share Attributab_2
Net Loss Per Share Attributable to Common Stockholders (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders | The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Non-vested Restricted Stock Units 346,006 359,750 Stock options to purchase common stock 6,595,473 3,425,444 Employee stock purchase plan 15,079 2,955 Total 6,956,558 3,788,149 |
Description of Business - Addit
Description of Business - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
Jan. 31, 2023 | Mar. 31, 2023 | |
Description Of Business [Line Items] | ||
Entity incorporation, date of Incorporation | Mar. 31, 2011 | |
Entity reincorporation, date of reincorporation | Oct. 27, 2015 | |
Net cash proceeds from issuance of convertible preferred stock, common stock warrants, and convertible notes | $ 407.4 | |
Cash, cash equivalents, and investments | $ 219.9 | |
At The Market Common Stock Offering | ||
Description Of Business [Line Items] | ||
Number of shares issued and sold | 0 | |
At The Market Common Stock Offering | Maximum | ||
Description Of Business [Line Items] | ||
Aggregate proceeds from issuance of common stock | $ 75 |
Significant Accounting Polici_4
Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | Dec. 31, 2021 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 105,182 | $ 95,966 | ||
Restricted cash | 631 | 420 | ||
Cash, cash equivalents and restricted cash | $ 105,813 | $ 96,386 | $ 118,021 | $ 110,537 |
Significant Accounting Polici_5
Significant Accounting Policies - Additional Information (Details) | 3 Months Ended | |||
Mar. 31, 2023 USD ($) Segment | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | |
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Grant income | $ 157,000 | $ 2,234,000 | ||
Unbilled grant receivable | $ 1,227,000 | |||
Accrued liabilities | $ 8,921,000 | 8,604,000 | ||
Number of operating segments | Segment | 1 | |||
Accounting Standards Update [Extensible Enumeration] | us-gaap:AccountingStandardsUpdate201613Member | |||
Change in accounting principle, accounting standards update, adoption date | Jan. 01, 2023 | |||
Change in accounting principle, accounting standards update, adopted | true | |||
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] | true | |||
National Institutes of Health Grant | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Grants received | $ 1,400,000 | 2,300,000 | ||
Grant income | 200,000 | $ 2,200,000 | ||
Aggregate grant income | 15,200,000 | |||
Unbilled grant receivable | $ 1,200,000 | |||
Additional grant income | $ 0 | |||
National Institute on Aging of the National Institutes of Health | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Research grant awarded | $ 15,200,000 |
Fair Value - Schedule of Fair V
Fair Value - Schedule of Fair Value of Cash Equivalents, Short-term Investments and Long-term Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents, Amortized Cost | $ 105,182 | $ 95,966 |
Recurring Basis | Short-term Investments | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Investments, Amortized Cost | 81,379 | 105,392 |
Investments, Unrealized Losses | (580) | (1,014) |
Investments, Fair Value | 80,799 | 104,378 |
Recurring Basis | Short-term Investments | Commercial Paper | Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Investments, Amortized Cost | 24,799 | 36,933 |
Investments, Unrealized Losses | (55) | (168) |
Investments, Fair Value | 24,744 | 36,765 |
Recurring Basis | Short-term Investments | Corporate Bonds | Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Investments, Amortized Cost | 3,302 | 3,302 |
Investments, Unrealized Losses | (29) | (62) |
Investments, Fair Value | 3,273 | 3,240 |
Recurring Basis | Short-term Investments | U.S. Government Debt and Agency Securities | Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Investments, Amortized Cost | 53,278 | 65,157 |
Investments, Unrealized Losses | (496) | (784) |
Investments, Fair Value | 52,782 | 64,373 |
Recurring Basis | Long Term Investments | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Investments, Amortized Cost | 34,336 | 45,745 |
Investments, Unrealized Gains | 22 | |
Investments, Unrealized Losses | (455) | (916) |
Investments, Fair Value | 33,903 | |
Investments, Fair Value | 44,829 | |
Recurring Basis | Long Term Investments | U.S. Government Debt and Agency Securities | Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Investments, Amortized Cost | 34,336 | 45,745 |
Investments, Unrealized Gains | 22 | |
Investments, Unrealized Losses | (455) | (916) |
Investments, Fair Value | 33,903 | |
Investments, Fair Value | 44,829 | |
Recurring Basis | Cash Equivalents | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents, Amortized Cost | 90,211 | 78,035 |
Cash equivalents, Unrealized Gains | 7 | |
Cash equivalents, Unrealized Losses | (23) | (26) |
Cash equivalents, Fair Value | 90,195 | 78,009 |
Recurring Basis | Cash Equivalents | Money Market Fund | Level 1 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents, Amortized Cost | 28 | 7 |
Cash equivalents, Fair Value | 28 | 7 |
Recurring Basis | Cash Equivalents | Commercial Paper | Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents, Amortized Cost | 72,459 | 78,028 |
Cash equivalents, Unrealized Losses | (23) | (26) |
Cash equivalents, Fair Value | 72,436 | $ 78,002 |
Recurring Basis | Cash Equivalents | Agency Securities | Level 2 | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Cash equivalents, Amortized Cost | 17,724 | |
Cash equivalents, Unrealized Gains | 7 | |
Cash equivalents, Fair Value | $ 17,731 |
Property and Equipment, Net - S
Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | $ 5,661 | $ 5,421 |
Less: accumulated depreciation | (1,603) | (1,368) |
Property and equipment, net | 4,058 | 4,053 |
Lab Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | 653 | 433 |
Office Furniture, Fixtures, and Computer Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | 712 | 692 |
Leasehold Improvement | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | $ 4,296 | $ 4,296 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 236,000 | $ 154,000 |
Accrued Liabilities - Schedule
Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Payables and Accruals [Abstract] | ||
Research and development expenses | $ 5,599 | $ 3,843 |
Employee compensation and benefits | 1,983 | 3,415 |
Professional services and other | 1,339 | 1,346 |
Total accrued Liabilities | $ 8,921 | $ 8,604 |
Significant Agreements - Additi
Significant Agreements - Additional Information (Details) - Washington State University License Agreement - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Dec. 31, 2020 | Dec. 31, 2015 | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
Milestone payments payable upon marketing approval | $ 600,000 | ||
Annual minimum royalty payments | 25,000 | ||
Net sales exempt from royalty payment | 100,000 | ||
Royalty obligation | $ 0 | ||
Licensed Products [Member] | |||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
Sales | $ 0 | ||
Phase 2 Clinical Trial Initiation | |||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
Milestone payments on development milestone achieved | $ 50,000 | ||
Phase 3 Clinical Trial Initiation | |||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
Milestone payments, amount payable | $ 300,000 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2022 | |
Commitments And Contingencies [Line Items] | |||
Legal settlement expense | $ 10,000 | ||
Proposed settlement on litigation | $ 10,000 | ||
Accrued legal settlement | $ 10,000 | $ 10,000 | $ 10,000 |
Wang V. Athira Pharma Inc., | |||
Commitments And Contingencies [Line Items] | |||
Lawsuit filing date | June 25, 2021 | ||
Name of plaintiff | Fan Wang and Hang Gao | ||
Jawandha V. Athira Pharma Inc., | |||
Commitments And Contingencies [Line Items] | |||
Lawsuit filing date | June 25, 2021 | ||
Name of plaintiff | Harshdeep Jawandha | ||
Slyne V. Athira Pharma Inc., | |||
Commitments And Contingencies [Line Items] | |||
Lawsuit filing date | June 25, 2021 | ||
Name of plaintiff | Timothy Slyne and Tai Slyne | ||
Athira Pharma Inc V Dr. Kawas | |||
Commitments And Contingencies [Line Items] | |||
Lawsuit filing date | August 12, 2022 | ||
Name of defendant | Dr. Kawas | ||
Laboratory and Office Facilities | Bothell, Washington | |||
Commitments And Contingencies [Line Items] | |||
Operating lease expiration month and year | 2027-08 | ||
Operating lease existence of option to extend | true | ||
Operating lease, additional term of contract | 5 years | ||
Laboratory and Office Facilities | Bothell, Washington | Minimum | |||
Commitments And Contingencies [Line Items] | |||
Operating lease initial term | 6 years 3 months 18 days | ||
Laboratory and Office Facilities | Bothell, Washington | Maximum | |||
Commitments And Contingencies [Line Items] | |||
Operating lease initial term | 7 years |
Commitments and Contingencies_2
Commitments and Contingencies - Reconciliation of Undiscounted Operating Lease Cash Flows to Operating Lease Liability Payments (Details) $ in Thousands | Mar. 31, 2023 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
Remaining 2023 | $ 351 |
2024 | 480 |
2025 | 494 |
2026 | 509 |
Thereafter | 346 |
Total undiscounted lease payments | 2,180 |
Present value adjustment for minimum lease commitments | (346) |
Net lease liability | $ 1,834 |
Commitments and Contingencies_3
Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Discount Rate to Determine the Operating Lease Liability (Details) | Mar. 31, 2023 |
Commitments and Contingencies Disclosure [Abstract] | |
Weighted average remaining lease term (years) | 4 years 4 months 24 days |
Weighted average discount rate | 8.10% |
Commitments and Contingencies_4
Commitments and Contingencies - Operating Lease Expense and Variable Lease Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Operating lease expense | $ 88,000 | $ 89,000 |
Variable lease expense | $ 60,000 | $ 44,000 |
Common Stock - Schedule of Rese
Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Details) - shares | Mar. 31, 2023 | Dec. 31, 2022 |
Class Of Stock [Line Items] | ||
Reserved shares of common stock for future issuance | 11,639,785 | 9,440,355 |
Shares Issuable Upon the Exercise of Outstanding Common Stock Options and the Vesting of Outstanding Common Restricted Stock Units Granted | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for future issuance | 6,941,479 | 4,269,861 |
Shares available for Future Grant under 2020 Equity Incentive Plan | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for future issuance | 3,402,892 | 4,253,854 |
Shares available for Future Grant under Employee Stock Purchase Plan | ||
Class Of Stock [Line Items] | ||
Reserved shares of common stock for future issuance | 1,295,414 | 916,640 |
Common Stock - Additional Infor
Common Stock - Additional Information (Details) - shares | 3 Months Ended | ||
Mar. 31, 2023 | Dec. 31, 2022 | Jan. 01, 2022 | |
Class Of Stock [Line Items] | |||
Reserved shares of common stock for future issuance | 11,639,785 | 9,440,355 | |
2020 Equity Incentive Plan | |||
Class Of Stock [Line Items] | |||
Share based compensation maximum annual increase in number of shares that may be issued under the plan | 3,230,000 | ||
Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding | 5% | ||
Reserved shares of common stock for future issuance | 1,893,869 | ||
2020 Employee Stock Purchase Plan | |||
Class Of Stock [Line Items] | |||
Share based compensation maximum annual increase in number of shares that may be issued under the plan | 646,000 | ||
Share based compensation percentage of number shares of common stock issued and outstanding on immediate proceeding | 1% | ||
Reserved shares of common stock for future issuance | 378,774 |
Stock-based Compensation - Stoc
Stock-based Compensation - Stock-based Compensation Expense Recognized (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 2,782 | $ 2,731 |
Research and Development | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 997 | 785 |
General and Administrative | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 1,785 | $ 1,946 |
Stock-based Compensation - Addi
Stock-based Compensation - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected dividend yield | 0% | |
Fair value of options granted | $ 7.6 | $ 11.9 |
Fair value of restricted stock units granted | 0.4 | 0.1 |
Fair value of options vested | 2.5 | 1.9 |
Aggregate intrinsic value of options exercised | 0.2 | $ 2.7 |
Unrecognized compensation cost | $ 23.7 | |
Remaining weighted-average period expected to recognize unrecognized compensation cost | 2 years 7 months 6 days | |
Restricted Stock Units (RSUs) | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Remaining weighted-average period expected to recognize unrecognized compensation cost | 10 months 24 days | |
Unrecognized stock-based compensation expense related to non-vested RSUs | $ 1.3 |
Stock-based Compensation - Weig
Stock-based Compensation - Weighted-Average Assumptions used in Estimating Fair Value of each Stock Options using Black-Scholes Option-Pricing Model (Details) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | ||
Risk-free interest rate | 3.48% | 1.73% |
Expected volatility | 99.25% | 92.65% |
Expected term (in years) | 5 years 9 months 18 days | 6 years 3 days |
Expected dividend yield | 0% |
Stock-based Compensation - Summ
Stock-based Compensation - Summary of Option Activity Changes in Shares Available for Grant under the 2020 Plan (Details) | 3 Months Ended |
Mar. 31, 2023 shares | |
Share-Based Payment Arrangement [Abstract] | |
Available for Grant, Beginning Balance | 4,253,854 |
2020 Plan reserve increase on January 1, 2023 | 1,893,869 |
Options and restricted stock units granted | (2,833,995) |
Options and restricted stock units forfeited, cancelled, or expired | 89,164 |
Available for Grant, Ending Balance | 3,402,892 |
Stock-based Compensation - Su_2
Stock-based Compensation - Summary of Option Activity under the 2020 Plan (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | ||
Shares, Beginning Balance | 4,033,522 | |
Shares, Granted | 2,714,995 | |
Shares, Exercised | (73,213) | |
Shares, Forfeited/expired | (79,831) | |
Shares, Ending Balance | 6,595,473 | 4,033,522 |
Shares, Expected to vest | 5,040,111 | |
Shares, Options exercisable | 1,555,362 | |
Weighted-Average Exercise price per Share, Beginning Balance | $ 11.75 | |
Weighted-Average Exercise price per Share, Granted | 3.52 | |
Weighted-Average Exercise price per Share, Exercised | 1.35 | |
Weighted-Average Exercise price per Share, Forfeited/expired | 5.34 | |
Weighted-Average Exercise price per Share, Ending Balance | 8.56 | $ 11.75 |
Weighted-Average Exercise price per Share, Expected to vest | 7.51 | |
Weighted-Average Exercise price per Share, Options exercisable | $ 11.96 | |
Weighted-Average Remaining Contractual Term (in years) | 8 years 10 months 2 days | 8 years 4 months 24 days |
Weighted-Average Remaining Contractual Term, Expected to vest (in years) | 9 years 2 months 19 days | |
Weighted-Average Remaining Contractual Term, Options exercisable (in years) | 7 years 7 months 9 days | |
Aggregate Intrinsic Value, Outstanding Balance | $ 476 | $ 827 |
Aggregate Intrinsic Value, Expected to vest | 67 | |
Aggregate Intrinsic Value, Options exercisable | $ 409 |
Stock-based Compensation - Su_3
Stock-based Compensation - Summary of Stock Options Outstanding and Exercisable under the 2020 Plan (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2023 | Dec. 31, 2022 | |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Shares Outstanding | 6,595,473 | 4,033,522 |
Shares Exercisable | 1,555,362 | |
Exercise Price $0.16 to 4.33 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Shares Outstanding | 3,206,263 | |
Shares Exercisable | 390,211 | |
Exercise Price $0.16 to 4.33 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise Price ($) | $ 0.16 | |
Exercise Price $0.16 to 4.33 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise Price ($) | $ 4.33 | |
Exercise Price $8.93 to 19.94 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Shares Outstanding | 3,015,489 | |
Shares Exercisable | 971,954 | |
Exercise Price $8.93 to 19.94 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise Price ($) | $ 8.93 | |
Exercise Price $8.93 to 19.94 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise Price ($) | $ 19.94 | |
Exercise Price $20.55 to 29.41 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Shares Outstanding | 373,721 | |
Shares Exercisable | 193,197 | |
Exercise Price $20.55 to 29.41 | Minimum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise Price ($) | $ 20.55 | |
Exercise Price $20.55 to 29.41 | Maximum | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise Price ($) | $ 29.41 |
Stock-based Compensation - Su_4
Stock-based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) | 3 Months Ended |
Mar. 31, 2023 $ / shares shares | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Share Equivalent, Non-vested, Beginning Balance | shares | 236,339 |
Share Equivalent, Granted | shares | 119,000 |
Share Equivalent, Cancelled | shares | (9,333) |
Share Equivalent, Non-vested, Ending Balance | shares | 346,006 |
Weighted-Average Grant Date Fair Value, Non-vested, Beginning Balance | $ / shares | $ 15.16 |
Weighted-Average Grant Date Fair Value, Non-vested, Granted | $ / shares | 3.37 |
Weighted-Average Grant Date Fair Value, Non-vested, Cancelled | $ / shares | 6.36 |
Weighted-Average Grant Date Fair Value, Non-vested, Ending Balance | $ / shares | $ 11.34 |
Net Loss Per Share Attributab_3
Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share | 6,956,558 | 3,788,149 |
Non-vested Restricted Stock Units | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share | 346,006 | 359,750 |
Stock Options to Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share | 6,595,473 | 3,425,444 |
Employee Stock Purchase Plan | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share | 15,079 | 2,955 |
Immaterial Error Correction (Un
Immaterial Error Correction (Unaudited) - Summary of Immaterial Errors Correction in the Weighted-Average Number of Common Shares Outstanding (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Weighted average shares outstanding,basic | 37,923,402 | 37,593,328 |
Weighted average shares outstanding, diluted | 37,923,402 | 37,593,328 |
Net loss per share, basic | $ (0.73) | $ (0.56) |
Net loss per share, diluted | $ (0.73) | $ (0.56) |